Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
Spikevax is an mRNA vaccine developed by Moderna that provides immunization against COVID-19 through intramuscular injection. The vaccine works by delivering messenger RNA that instructs cells to produce the SARS-CoV-2 spike protein, triggering an immune response. It represents a major advancement in vaccine technology and pandemic response.
Recently approved vaccine in active launch phase with moderate competitive pressure (30), indicating sustained team expansion and market development opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
Worked on Spikevax at Moderna? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Moderna is hiring 1 role related to this product
Working on Spikevax offers exposure to a landmark vaccine product with 153 active job openings across R&D, Manufacturing, Engineering, and Regulatory functions. Career growth is strongest in technical and operational roles, reflecting the product's launch phase and manufacturing scale-up demands.
153 open roles linked to this drug
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo